These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 33771173)

  • 1. Identification of 4 immune cells and a 5-lncRNA risk signature with prognosis for early-stage lung adenocarcinoma.
    Mu L; Ding K; Tu R; Yang W
    J Transl Med; 2021 Mar; 19(1):127. PubMed ID: 33771173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma.
    Zhou H; Zhang H; Chen J; Cao J; Liu L; Guo C; Huang G; Zeng D
    J Cell Biochem; 2019 Sep; 120(9):15730-15739. PubMed ID: 31050375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
    Ma C; Gu Z; Yang Y
    J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
    Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
    Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A methylation-related lncRNA-based prediction model in lung adenocarcinomas.
    Yang K; Liu H; Li JH
    Clin Respir J; 2024 Aug; 18(8):e13753. PubMed ID: 39187946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.
    Chen M; Liu B; Xiao J; Yang Y; Zhang Y
    Oncotarget; 2017 Feb; 8(9):14876-14886. PubMed ID: 28122330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
    Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
    Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma.
    Chen Y; Zhang X; Li J; Zhou M
    J Clin Lab Anal; 2021 Nov; 35(11):e24018. PubMed ID: 34550610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
    Ren J; Wang A; Liu J; Yuan Q
    Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.
    Zheng J; Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Li Z; Ming L; Qin Z
    J Clin Lab Anal; 2021 Nov; 35(11):e23951. PubMed ID: 34558724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
    Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma.
    Zhou S; Cai Y; Xu Z; Peng B; Liang Q; Peng J; Yan Y
    Front Endocrinol (Lausanne); 2022; 13():964362. PubMed ID: 36034461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of prognostic biomarkers in lung adenocarcinoma based on aberrant lncRNA-miRNA-mRNA networks and Cox regression models.
    Yao Y; Zhang T; Qi L; Liu R; Liu G; Wang J; Song Q; Sun C
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31950990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.
    Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y
    Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
    Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
    J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
    Li F; Ge D; Sun SL
    BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.